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Abstract
Head and neck squamous cell carcinoma (HNSCC), a significant cause of cancer deaths worldwide, has multiple
stepwise malignant evolutions. Mammalian target of rapamycin (mTOR) plays a critical role in tumor development,
invasion, metastasis and angiogenesis that impact local recurrence and survival. mTOR can also act as a biomarker
for personalized adjuvant therapy. In in vivo and in vitro studies, mTOR inhibitor suppresses tumor growth and
sensitizes HNSCC to radiation, cytotoxic agents and epidermoid growth factor receptor inhibitors. We have
reviewed the pathogenesis of HNSCC, mTOR pathway, mTOR inhibitor and the role of mTOR in HNSCC.
Review
Head and neck squamous cell carcinoma (HNSCC) is
the sixth most common cancer worldwide and accounts
for approximately 650,000 new diagnoses and 350,000
cancer deaths every year [1]. Smoking and alcohol are
the most well known carcinogens of HNSCC [2]. In
some areas of Asia, chewing betel quid, a psychoactive
substance that always contains areca nut, betel leaf and
calcium hydroxide, is a distinct risk factor that exerts a
synergistic effect with smoking and alcohol consumption
for oral and laryngeal cancer [3,4]. In addition, the con-
tinuation of smoking and alcohol consumption after
initial diagnosis of HNSCC increases the risk for sec-
ondary primary cancer [5]. Human papillomavirus
(HPV), predominantly type 16, infection inducing geno-
mic instability is another mechanism for tumorigenesis
in the oropharynx that is distinct from the role of smok-
ing or alcohol [6].
Surgery and radiotherapy are the main modality of
HNSCC treatment [7]. Chemotherapy, acting as a radio-
sensitizer, increases survival in locally advanced disease
[8,9]. To treat early disease, surgery is preferred. Radio-
therapy is an alterative method for organ preservation
for laryngeal cancer [10,11]. In unresectable settings,
concurrent cisplatin chemoradiotherapy that provides
better disease free survival and overall survival than
radiotherapy alone is the standard of care [9]. Surgery-
treated, advanced patients with high risk factors can also
obtain benefit of local and regional control and progres-
sion free survival by adding concurrent chemotherapy to
postoperative radiotherapy [12]. Overall, the incorpora-
tion of concurrent chemoradiotherapy to management
of HNSCC absolutely increases survival rate by 6.5% at
year-five [13]. Recently, cetuximab, an epidermal growth
factor receptor-specific monoclonal antibody, plus radia-
tion were shown to improve survival rate as compared
to radiation treatment alone [14]. However, a retrospect
study suggests the duration of progression free survival
and overall survival is shorter in patient receiving cetux-
imab plus radiation than those with cisplatin plus radia-
tion [13]. Multi-modality treatment or targeted therapy
containing management does not significantly improve
overall survival.
HNSCC has a complex mechanism of carcinogenesis
that involves multiple genetic abnormalities, stepwise
evolution and signaling pathway alternation [7,15-18].
Alternations of p53, p16 and cyclin D1 (CCND1) result
in limitless growth of tumor cells [4,19-22]. Change of
epidermal growth factor receptor (EGFR), c-MET, phos-
phatidylinositol 3-kinase, catalytic, alpha polypeptide
(PIK3CA), Ras-mitogen-activate protein kinase (Ras-
MAPK), phosphatase and tensin homolog (PTEN) and
transforming growth factor-beta (TGF-beta) are essential
to affect growth factor signaling that impact cell prolif-
eration, apoptosis and survival [23-28]. High expression
of nuclear factor Kappa B (NF-Kappa B), surviving and
B cell lymphoma -2 (Bcl-2) are positively associated
with poor survival [29-31].
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Mammalian TOR (mTOR), a protein kinase encoded by
FK506 binding protein 12-rapamycin associated protein
1 (FRAP1) gene [32]., is an important downstream tar-
get signal of PI3K pathway. (Figure 1) [33]. The protein
contains an 12-kDa FK506-binding protein (FKBP12),
rapamycin binding domain, Huntington Elongation Fac-
tor 3 PR65/ATOR (HEAT) motifs, FK506 binding pro-
tein 12-rapamycin associated protein (FRAP1)-ataxia
telangiectasia mutated (ATM)-transformation transcrip-
tion domain-associated protein (FAT) and FAT C termi-
nus (FATC) domain. In terms of structure and function,
mTOR consists of two distinct complexes: mTOR com-
plex 1 (mTORC1) and mTOR complex 2 (mTORC2)
[34,35]. mTOR, regulatory-associated protein of mTOR
(Raptor) and G-protein-subunit-like protein form
mTORC1, a nutrition-sensitive complex. mTORC1 is
sensitive to rapamycin, control cell growth and is a key
factor of the mTOR pathway [34-38]. mTORC2, a com-
plex containing mTOR, G-protein-subunit-like protein
and mAVO3, regulates the actin cytoskeleton and is
insensitive to rapamycin [39]. As an important target
kinase of the PI3K pathway, mTOR responds to multiple
stimuli including: nutrients, insulin, oxygen, growth fac-
tor, ATP, Ras homologue enriched in brain (RHEB) and
tobacco components [33,38,40-44]. However, mTOR is
negatively regulated by complex of tuberin and hamartin
[45]. Through the activation of two downstream targets
p70S6K and 4EBP1, mTOR functions on translation, cell
growth, protein synthesis, cell size and angiogenesis
[46-48]. Activated p70S6K stimulates 5-terminal oligo-
pyrimidine (5’TOG) translation to regulate ribosome
biogenesis [49]. Phosphorylated 4EBP1 disassociates
with eIF4E. The free eIF4E, an oncoprotein, promotes
cap-dependent translation with subsequent regulation of
c-myc, cyclin D1, ornithinedecarboxylase, basic fibro-
blast growth factor (b-FGF), vascular endothelial growth
factor (VEGF) and matrix metalloproteinase-9 (MMP-9)
to affect cell survival, tumorigenesis and transformation,
angiogenesis, invasion and metastasis [41,50-54]. In
addition, mTOR-enhanced expression of HIF-1a protein,
HIF-1 transcriptional activity, and VEGF protein are the
key regulators in angiogenesis [55]. Apoptosis signal-
regulating kinase 1 (ASK1)-modulated apoptosis can be
inhibited by mTOR-induced overexpression of protein
phosphatase 5 (PP5) [56].
mTOR inhibitor
Many compounds, including rapamycin, rapalog and
adenosine-5’-triphosphate (ATP)-competitive inhibitor,
have been shown to block the activation of the mTOR
pathway [57]. Rapamycin, an antifungal agent, [58].
binds to the FKBP12-rapamycin (FRB) domain of
mTORC1 to interrupt downstream activation [59]. Poor
water solubility, absorption, limited bio-availability,
hepatic first-pass effect and drug interaction account for
interpatient variability that requires therapeutic drug
monitoring for the complex pharmacokinetic behaviors
[60]. Although rapamycin is a promisingly cytostatic
anticancer agent in the National Cancer Institute’s
screening program, [35]. those pharmacologic character-
istics limit the practical application [61,62]. In order to
improve the pharmacokinetic features of rapamycin, a
chemical modification at C-40-0 can develop three new
rapalogs including everolimus, temsirolimus and ridafor-
olimus that share the same mechanisms of action. They
not only exert anti-cancer activity but also act as a sen-
sitizer to radiotherapy and chemotherapy. Frequent
adverse events such as fatigue, mucositis, rash, anorexia,
diarrhea, nausea, thrombocytopenia, leucopenia, anemia,
hyperglycemia, hyperlipidemia and hypercholesterolemia
Figure 1 Mammalian target of rapamycin is a key regulator in
development and progression of cancer. Mammalian target of
rapamycin responds to stimuli of growth factor, insulin, tobacco
components, nutrients, hypoxia, ATP and RHEB to activate P70S6
and inhibit 4EBP1 and PP5 with subsequent dysregulation of
apoptosis, cell survival, cell transformation, tumorigenesis,
angiogenesis, invasion and metastasis. PI3K, phosphatidylinositol 3-
kinase; ATP, adenosine triphosphate; RHEB, ras homologue enriched
in brain; mTORC1, mammalian target of rapamycin complex 1; PP5,
protein phosphatase 5; ASK1, apoptosis-signal-regulating kinase 1;
p70S6, ribosomal p70 S6; EIF4E, eukaryotic translation initiation
factor 4E; 4E-BP1, EIF4E-binding protein 1.
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is an oral rapalog, and has better oral absorption and
bioavailability profiles than compared to those of rapa-
mycin [64,65]. It also shows sustained inhibition of
S6K1 activity at the dose of ≥ 20 mg weekly and ≥ 5m g
daily [66]. Temsirolimus is a prodrug converted into
rapamycin after intravenous infusion. It exerts evidence
of activity over a dose range between 15 and 300 mg/
m
2, and has the dose-limiting toxicity from thrombocy-
topenia [67]. Ridaforolimus is a non-prodrug rapalog,
and has dose limiting toxicity from mouth sore at 28
mg/d and maximal tolerable dose of 18.5 mg/d [68]. In
a study of skin biopsy specimens, ridaforolimus signifi-
cantly suppressed the expression of 4EBP1, S6 and
extracellular signal-regulated kinase (ERK) [69].
mTOR pathway and HNSCC
HNSCC amplifies eukaryotic translation initiation factor
4E(eIF4E) gene and overexpresses eIF4E protein [70].
The tumor itself, the surgical margins, and even the his-
tologically normal epithelium in the margins were all
shown to overexpress eIF4E. The strong association of
elevated activity of eIF4E with high expression of mTOR
downstream signals transduction (phospho-4E binding
protein 1, S6, phospho-mTOR) and elevated level of
AKT expression suggests the activation of AKT/mTOR
pathway in the margin. High expression of phospho-
P70S6 and AKT in the margin indicates that the activity
of AKT/mTOR cascade is higher in tumor margin than
in the tumor itself [71]. There is a significant correlation
between degree of expression of eIF4E in the margin
and grading of the dysplasia (P = .006) [72]. eIF4E is
essential in the malignant progression of HNSCC [70].
Interestingly, higher activity of eIF4E in the tumor mar-
gin, even those free of microscopic tumor, is an inde-
pendent predictor of local recurrence while histological
grading of dysplasia failed to predict prognosis [73].
Nathan et al examined tumor samples from 65 patients.
A l lb i o p s i e se x p r e s s e de l e v a t e dl e v e l so fe I F 4 E .T h e
intra-tumor activity of eIF4E was not different between
the eIF4E-positive and -negative margin groups. Thirty-
six patients (55%) with microscopic tumor-free margins
had eIF4E expression in the basal cell layer of the mar-
gin. After a median follow-up of 17 months, local-regio-
nal recurrence developed in 20 patients (56%) with
eIF4E-positive margins. In contrast, two patients (6.9%)
with absence of eIF4F expression had local recurrence
after median follow-up of 14.5 months. Histologically
tumor-free margin with high expression of eIF4E has a
seven-fold risk of local failure. The median disease free
duration is significantly shorter in the eIF4E positive
margin group (eIF4E positive versus negative, 11 months
versus 14 months; log-rank test, P = .0001). The predic-
tion of recurrence by expression of eIF4E in HNSCC
margin is independent from tumor size, nodal status,
stage, histologic grade, tumor site, eIF4E levels in the
tumor, and with the degree of dysplasia in the margins
[72]. Also, the level of p-S6 expression significantly
increases with the malignant progression of the tumor
[74]. In addition, irradiation, an important treatment of
HNSCC, promotes the expression of mTOR and AKT
in HNSCC cells [75]. High expression of AKT sensitizes
mTOR inhibition through down-regulation of cyclin D1
and c-myc [76,77]. Activation of AKT/mTOR pathway
plays a key role in tumorigenesis and survival rate of
HNSCC patients [71]. The eIF4E is a potential maker to
define the molecular-free surgical margin, and is a pro-
mising predictor of survival [72,73].
mTOR inhibitor and HNSCC
Temsirolimus blocks the activation of mTOR pathway
in HNSCC cell line to reduce the expression of S6 and
4EBP1 with subsequently suppressed expression of FGF
and VEGF that inhibited cell growth in vitro. In a xeno-
graft study, the 4EBP1 activity of tumor cells and per-
ipheral blood mononuclear cells (PBMC) is also reduced
by mTOR inhibition [78,79]. Rapamycin treatment
increased nuclei apoptosis in tumor in situ TUNEL
assay, and reduced neovascularization [74]. To mimic
patients with histologically tumor-free margin with high
expression of eIF4E, the tumor cells in the culture med-
ium were introduced into the dorsal flap of nude mice
with pipettes to establish a minimal residual disease
model (MRD). Measuring the tumor formation at day
21 after xenograft, the treatment group had a signifi-
cantly longer median tumor free duration (treatment
versus control group, 18 days versus 7 days; P < 0.0001).
The tumor size of treatment group was significantly
smaller than those of the control group (P < 0.0001). In
the “survival study” mTOR inhibition delayed the time
to develop tumors with the volumes of at least 200 m
3
in the MRD model (P < 0.0001). Twenty-one percent of
the treated mice were free of tumors 30 days after the
discontinuation of the treatment. As expected, temsiroli-
mus treatment significantly reduced photon emission on
bioluminescence imaging. The reduction increased with
the continuation of the treatment. The result of the
MRD model suggests that the prolonged mTOR inhibi-
tion may have clinical benefits in the adjuvant setting
for patients with eIF4E positive margin [78]. mTOR
inhibitor is a potential agent in HNSCC treatment.
Phosphorylated mTOR, eIF4E, and high expression of
AKT may be potentional biomarkers in order to select
the candidate HNSCC patients for mTOR inhibitor-
based adjuvant therapy [71,77,80].
Everolimus enhances DNA-damage agent-induced
apoptosis in tumor cells. It overcomes cisplatin resis-
tance in small cell and non-small cell lung cancer cell
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arresting cells in G2M phase [79,83,84]. In an in vivo
study, temsirolimus was shown to block signal transduc-
tion of mTOR pathway to decrease VEGF production,
but failed to sensitize HNSCC to radiation by clono-
genic assay. In a study with cisplatin-sensitive Fa-Du
and cisplatin-resistant SCC-40 xerografts receiving 3-
week treatment with temsirolimus or cisplatin plus
radiation, temsirolimus alone treatment, even at low
doses, significantly blocked the tumor growth in both
xenografts. The combination of temsirolimus with radia-
tion (XRT) more significantly promoted radiation-
induced tumor reduction (P < 0.05; temsirolimus plus
XRT versus. temsirolimus or XRT alone) than compared
to the combination of cisplaint with XRT alone in both
cisplaitn- sensitive and resistant cell lines (P < 0.05).
Addition of cisplatin to the temsirolimus and XRT treat-
ment failed to increase the therapeutic effect. The sensi-
tization effect by temsirolimus is evidenced by the
following: the reduced phosphorylation of 4EBP1, S6
and Bad; the increased number of radiation-related poly
(ADP-ribose) polymerases (PARPs) cleavage; the
increased rate of nuclei apoptosis; and the reduction of
tumor vascularity by diminishing VEGF production. The
median survival time was 49 days for the temsirolimus
plus XRT treatment group, 38 days for the cisplatin plus
XRT treatment group and 27 days for the control group
for the SCC-40 cell lines. Treatment with temsirolimus
alone or with the combination of XRT can significantly
increase the survival rate of SCC-40 xenograft as com-
pared to the control group (P < 0.05). mTOR inhibitor
is a promising radio-sensitizer in HNSCC treatment
[75]. Although EGFR is an important target of therapy,
[85]. HNSCC poorly responds to or is refractory to anti-
EGFR treatment. In HNSCC cell lines Detroit 562, erlo-
tinib blocks the activation of MAPK and suppresses the
expression of AKT and p70. Temsirolimus alone failed
to affect AKT and MAPK. The MAPK was completely
blocked by the combination treatment while the activity
of AKT was significantly inhibited. In an in vivo study,
the combination therapy, erlotinib alone therapy, and
the temsirolimus alone therapy obtained growth rates
that was 18%, 34% and 13% of the rate of growth of the
control group, respectively. Seven days after the treat-
ment, the expression of pMAPK, Ki-67 and phospho-
p70 were significantly reduced. mTOR inhibition sup-
pressed tumor growth of EGFR-resistant cell lines and
exerted an additive effect with the combination of the
EGFR inhibitor [86].
7Few HNSCC patients were enrolled into a phase 1
study to investigate the safety of an mTOR inhibitor
based combination therapy. A patient with HNSCC
T4N3M1 with lung metastasis with failed responses to
docetaxel, cisplatin and zalutumumab partially
responded to temsirolimus and metformine [87]. One
oropharyngeal cancer patient obtained stable disease
Table 1 Clinical study for mTOR inhibitor in treatment of HNSCC
Drug Study
phase
Treatment design Disease status Clinicaltrial.gov
identifier
Rapamycin I/II Neoadjuvant with 21-day rapamycin followed by
surgery
Stage III or IVA, resectable NCT01195922
Temsirolimus II Temsirolimus with or without cetuximab Recurrent or metastasis NCT01256385
II Temsirolimus alone Recurrent or metastasis NCT01172769
I/II Temsirolimus + Weekly paclitaxel + carboplatin Recurrent or metastasis NCT01016769
I/II Temsirolimus, cisplatin, and cetuximab Recurrent or metastasis NCT01015664
II Temsirolimus and erlotinib Platinum-refractory or -ineligible, advanced
disease
NCT01009203
Everolimus I Everolimus, weekly cisplatin and XRT Locally advanced NCT01058408
I Induction with everolimus, docetaxel, and cisplatin Locally advanced NCT00935961
I Everolimus, weekly cisplatin and XRT Locally advanced NCT00858663
I Everolimus, cisplatin and XRT Locally advanced NCT01057277
I/II Induction everolimus paclitaxel, and cisplatin Locally advanced NCT01133678
II,
randomized
Adjuvant everolimus Vs placebo Locally advanced disease after definite local
treatment
NCT01111058
I/IIB Everolimus, carboplatin, and cetuximab Recurrent or metastaasis NCT01283334
I/II Everolimus, cetuximab and cisplatin Recurrent or metastaasis NCT01009346
II Everolimus Refractory, recurrent or metastasis NCT01051791
II Everolimus, erlotinib Recurrent NCT00942734
Ridaforolimus I Ridaforolimus, cetuximab Advanced NCT01212627
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and weekly cisplatin. No change of expression of p21,
p53 or p-AKT was found on a biopsy specimen from
pretreatment and day 21 on treatment [88].
Many studies have been initiated to elucidate the role
of mTOR inhibitor in the treatment of HNSCC (Table
1). National Institutes of Dental and Craniofacial
Research initiated a pilot study to investigate the efficacy
and molecular change of neoadjuvant 3-week treatment
of rapamycin in resectable HNSCC patients. Molecular
study of the specimens obtained from tumor biopsies
during the period of treatment provides further informa-
tion for clinical response to rapamycin (clinicaltrial.gov
identifier: NCT01195922). One future randamized phase
II trial of everolimus versus placebo as an adjuvant ther-
apy in patients with locally advanced HNSCC
(NCT01111058) will evaluate the benefit of long-term
mTOR inhibition in patients with eIF4E positive margin
[78]. Some trials will test the safety at different dosages
and determine the optimal dose of mTOR inhibitor in
combination with radiation or cytotoxic agents.
Conclusion
mTOR plays an important role in the complex carcino-
genesis of HNSCC, predicts survival, and may be a
potential biomaker to identify candidate patients for
mTOR inhibition-based adjuvant therapy. Many precli-
nical experements suggest that the mTOR blockade has
anti-tumor activity, displays radio- or chemo-sensitiza-
tion, and overcomes the EGFR resistance. Further clini-
cal trial results may provide more information about the
role of mTOR in future studies and management of
HNSCC.
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